[PDF][PDF] Proliferation marker Ki-67 in early breast cancer

A Urruticoechea, IE Smith… - Journal of clinical oncology, 2005 - researchgate.net
Journal of clinical oncology, 2005researchgate.net
Molecular markers have been extensively investigated with a view to providing early and
accurate information on long-term outcome and prediction of response to treatment of early
breast cancer. Proliferation is a key feature of the progression of tumors and is now widely
estimated by the immunohistochemical assessment of the nuclear antigen Ki-67. The
expression of Ki-67 correlates with other measurements of proliferation, including S-phase
and bromodeoxyuridine uptake. High Ki-67 is a sign of poor prognosis associated with a …
Molecular markers have been extensively investigated with a view to providing early and accurate information on long-term outcome and prediction of response to treatment of early breast cancer. Proliferation is a key feature of the progression of tumors and is now widely estimated by the immunohistochemical assessment of the nuclear antigen Ki-67. The expression of Ki-67 correlates with other measurements of proliferation, including S-phase and bromodeoxyuridine uptake. High Ki-67 is a sign of poor prognosis associated with a good chance of clinical response to chemotherapy, but its independent significance is modest and does not merit measurements in most routine clinical scenarios. However, its application as a pharmacodynamic intermediate marker of the effectiveness of medical therapy holds great promise for rapid evaluation of new drugs.
researchgate.net